



## UNITED STATES PATENT AND TRADEMARK OFFICE

11/2 SFW  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/659,045	09/09/2003	Siegfried Franke	HOE-776	3269
20028	7590	05/12/2006		
Lipsitz & McAllister, LLC 755 MAIN STREET MONROE, CT 06468				
		O P E IAPAC MAY 17 2006 PATENT & TRADEMARK OFFICE	EXAMINER CHONG, YONG SOO ART UNIT 1617	PAPER NUMBER

DATE MAILED: 05/12/2006

- Please find below and/or attached an Office communication concerning this application or proceeding.



## Office Action Summary

The MAILING DATE of this communication appears on the cover sheet with the correspondence address -- Period for Reply	Application No.	Applicant(s)
	10/659,045	FRANKE ET AL.
	Examiner Yong S. Chong	Art Unit 1617

The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) Responsive to communication(s) filed on 17 March 2006.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) 8-11 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-7 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|  | 6) <input type="checkbox"/> Other: _____                                    |

## DETAILED ACTION

### ***Status of the Application***

This Office Action is in response to applicant's arguments filed on 3/17/2006. Claims 8-11 have been withdrawn. Claim 1 has been amended. Claims 1-7 are pending and are examined herein. Applicant's arguments have been fully considered but found not persuasive. The 35 USC 103(a) rejection is repeated below and maintained for reasons of record.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Franke et al. (DD 299458, relying on 117CA:106200 as an English language abstract) in view of Wolthers et al. (DD 301726, relying on 120CA:99206 as an English language abstract), Hill et al. (USPN 6723349) and Fuchs et al. (USPN 4284645).

Franke et al. teaches a detoxicant comprising 0.5-2.6M sodium; 10-60% of an amino alcohol, preferably dimethylaminoethanol; 0-20% of an alcohol; 20-80% of an alkylcaprolactam; and, optionally, benzene or cyclohexane. Alcohols, such as methanol, ethanol and propanol are disclosed. See page 1, line 37 of the patent. It is noted that the addition of sodium to the composition will, necessarily, produce a sodium

Art Unit: 1617

alkoxide and/or a sodium aminoalkoxide. Franke et al. does not specifically teach the claimed compounds (i.e., a C2-C5 acid amide and/or a C2-C6 diamine).

Wolthers et al. teaches a detoxicant comprising an alkali metal, such as sodium; an amino alcohol, such as aminoethanol; an alcohol, such as butanol; and a strongly polar solvent, such as DMSO.

Hill et al. teaches a decontaminating composition comprising a solvent selected from, e.g., NMP and DMSO.

Fuchs et al. teaches both NMP and DMSO to be known in the chemical art as strongly polar solvents.

It would have been obvious to one of ordinary skill in the art at the time of the invention to substitute the alkylcaprolactam of Franke et al. with NMP (or a C4-C5 lactam) because (1) alkylcaprolactam is a C6 lactam (acid amide); (2) NMP is a C3 lactam; (3) absent unexpected properties, adjacent homologs are generally considered to be obvious, *In re Hass*, 141 F.2d 127, 60 USPQ 548 (CCPA 1944); *In re Henze*, 85 USPQ 261 (CCPA 1950); (4) Wolthers et al. teaches that the solvent of a detoxicant comprising an amino alcohol, an alcohol and an alkali metal need only be strongly polar; (5) DMSO and NMP are both known in the art to be strongly polar; and (6) both NMP and DMSO are both known in the art to be useful as solvents of decontaminating agents. One would have been motivated to substitute the alkylcaprolactam of Franke et al. with NMP because of an expectation of similar success in preparing a detoxicant.

***Response to Arguments***

Applicant argues that the ranges of each component is so different that the composition leads to different properties even though most ranges are encompassed in the prior art and at least all components meet at the limit.

At the outset, Examiner respectfully reminds the Applicant that a composition and its properties are inseparable. Furthermore, it is obvious to optimize the ranges of a component in a composition where the general range is disclosed.

"Products of identical chemical composition can not have mutual exclusive properties." Any properties exhibited by or benefits from are not given any patentable weight over the prior art provided the composition is inherent. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the disclosed properties are necessarily present. *In re Spada*, 911 F.2d 705, 709, 15 USPQ 1655, 1658 (Fed. Cir. 1990). See MPEP 2112.01. The burden is shifted to the applicant to show that the prior art product does not inherently possess the same properties as the instantly claimed product.

Generally, mere optimization of ranges will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "When the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimal or workable ranges by routine experimentation. *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also *In re Peterson*, 315 F. 3d at 1330, 65 USPQ 2d at 1382 "The normal desire of scientists or artisans to improve upon what is already generally known

provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages." MPEP 2114.04.

Applicant also argues surprising results for a decontaminating fluid that is mild on the substrate. The burden is shifted to Applicant to show clear and convincing factual evidence of nonobviousness or unexpected results, i.e., side-by-side comparison with the closest prior art in support of nonobviousness for the instant claimed invention over the prior art. For the above stated reasons, said claims are properly rejected under 35 U.S.C.103(a). Therefore, said rejections are adhered to.

Applicant continues to argue that replacing a component of the instant invention with "a polar solvent like DMSO would result in a drastic decrease in decontamination efficiency or, put another way, would require a completely different balancing of the various ingredients of a decontamination liquid in order to make it efficient."

Optimization of the various components of a composition when the general range is disclosed is as discussed above. More importantly, DMSO was merely used in the rejection as a nexus to substitute NMP for DMSO in a detoxicant composition because both are disclosed to be polar solvents. Thus, the motivation is because of the art equivalency of both solvents.

Finally, Applicant argues that the intended use is not concurrent with the instant invention, specifically referring to the referenced invention being far too aggressive to be applied to the skin of a living organism. Examiner respectfully points out the fact that the intended use or preamble of a composition is given little patentable weight.

It is respectfully pointed out that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the

prior art in order to patentably distinguish from each other. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963). Thus, the intended use of a composition claim will be given no patentable weight.

It is further respectfully pointed out that a preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to stand alone. See *In re Hirao*, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and *Kropa v. Robie*, 187 F.2d 150, 152, 88 USPQ 478, 481 (CCPA 1951). See MPEP 2111.02.

### ***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1617


the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached on M-F, 9-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, SREENI PADMANABHAN can be reached on (571)-272-0629. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

YSC

  
SHENGJUN WANG  
PRIMARY EXAMINER

Application Number	Application/Control No.	Applicant(s)/Patent under Reexamination
	10/659,045	FRANKE ET AL.
	Examiner	Art Unit
	Yong S. Chong	1617



**Index of Claims**

Application/Control No.

10/659,045

Applicant(s)/Patent under  
Reexamination

FRANKE ET AL.

Examiner

Yong S. Chong

Art Unit

1617

/	Rejected
=	Allowed

-	(Through numeral) Cancelled
+	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

Claim	Date	
Final	Original	
1	✓	5/2/06
2	✓	
3	✓	
4	✓	
5	✓	
6	✓	
7	✓	
8	N	
9	N	
10	N	
11	N	
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		

Claim	Date	
Final	Original	
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		
65		
66		
67		
68		
69		
70		
71		
72		
73		
74		
75		
76		
77		
78		
79		
80		
81		
82		
83		
84		
85		
86		
87		
88		
89		
90		
91		
92		
93		
94		
95		
96		
97		
98		
99		
100		

Claim	Date	
Final	Original	
101		
102		
103		
104		
105		
106		
107		
108		
109		
110		
111		
112		
113		
114		
115		
116		
117		
118		
119		
120		
121		
122		
123		
124		
125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		
138		
139		
140		
141		
142		
143		
144		
145		
146		
147		
148		
149		
150		

<b>Search Notes</b> 	<b>Application/Control No.</b> 10/659,045	<b>Applicant(s)/Patent under Reexamination</b> FRANKE ET AL.
<b>Examiner</b> Yong S. Chong	<b>Art Unit</b> 1617	